0001021771-24-000091.txt : 20240410 0001021771-24-000091.hdr.sgml : 20240410 20240410171636 ACCESSION NUMBER: 0001021771-24-000091 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240408 FILED AS OF DATE: 20240410 DATE AS OF CHANGE: 20240410 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Silva Francisco CENTRAL INDEX KEY: 0001527241 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37603 FILM NUMBER: 24836607 MAIL ADDRESS: STREET 1: STEM CELL ASSURANCE, INC. STREET 2: 555 HERITAGE DRIVE CITY: JUPITER STATE: FL ZIP: 33458 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BioRestorative Therapies, Inc. CENTRAL INDEX KEY: 0001505497 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 301341024 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 40 MARCUS DRIVE CITY: MELVILLE STATE: NY ZIP: 11747 BUSINESS PHONE: (631) 760-8100 MAIL ADDRESS: STREET 1: 40 MARCUS DRIVE CITY: MELVILLE STATE: NY ZIP: 11747 FORMER COMPANY: FORMER CONFORMED NAME: Stem Cell Assurance, Inc. DATE OF NAME CHANGE: 20101110 4 1 form4.xml X0508 4 2024-04-08 0001505497 BioRestorative Therapies, Inc. BRTX 0001527241 Silva Francisco C/O BIORESTORATIVE THERAPIES, INC. 40 MARCUS DRIVE MELVILLE NY 11747 true true VP of Research and Development false Common Stock 2024-04-08 4 P 0 476 1.13 A 147927 D Common Stock 2024-04-08 4 P 0 1232 1.17 A 149159 D Common Stock 2024-04-09 4 P 0 6600 1.25 A 155759 D Common Stock 12136 I IRA Stock Option 3000 2024-10-23 Common Stock 9 9 D Stock Option 3000 2025-09-04 Common Stock 6 6 D Stock Option 3000 2026-06-10 Common Stock 15 15 D Stock Option 3000 2027-07-12 Common Stock 20 20 D Stock Option 3000 2028-10-29 Common Stock 25 25 D Stock Option 5.08 2031-03-18 Common Stock 293479 293479 D Stock Option 5.08 2031-11-04 Common Stock 42059 42059 D Stock Option 2.91 2033-02-17 Common Stock 106762 106762 D Stock Option 1.45 2034-02-13 Common Stock 394737 394737 D The option is currently exercisable. The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 and 21,029 shares in eight nearly equal quarterly installments beginning November 4, 2022 and continuing every three months thereafter until fully vested. The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 and 53,381 shares in eight nearly equal quarterly installments beginning February 17, 2024 and continuing every three months thereafter until fully vested. The option vests and becomes exercisable to the extent of 197,369 shares on February 13, 2024 and 197,368 shares in eight nearly equal quarterly installments beginning February 13, 2025 and continuing every three months thereafter until fully vested. /s/ Francisco Silva 2024-04-10